Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis - PubMed (original) (raw)
Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis
Matthew M Ford et al. Drug Alcohol Depend. 2008.
Abstract
The neurosteroid allopregnanolone (ALLO) is a positive modulator of GABA(A) receptors that exhibits a psychopharmacological profile similar to ethanol (i.e., anxiolytic, sedative-hypnotic). Based on research suggesting that manipulation of ALLO levels altered ethanol self-administration in male rodents, the current studies determined whether exogenous ALLO administration or the inhibition of its synthesis in vivo modulated ethanol intake patterns in female C57BL/6J mice. Lickometer circuits collected temporal lick records of ethanol (10%, v/v) and water consumption during daily 2h limited access sessions. Following the establishment of stable ethanol intake, studies examined the effect of an acute ALLO challenge (3.2-24.0 mg/kg) or a 7-day blockade of ALLO production with finasteride (FIN; 50 or 100 mg/kg) on ethanol intake in a within-subjects design. In contrast to results in male mice, ethanol dose (g/kg), ethanol preference and most of the bout parameters were unaltered by ALLO pretreatment in female mice. Ethanol intake in females also was recalcitrant to 7-day treatment with 50 mg/kg FIN, whereas 100 mg/kg FIN significantly reduced the ethanol dose consumed by 35%. The FIN-attenuated ethanol intake was attributable to a significant decrease in bout frequency (up to 45%), with lick patterns indicating reduced maintenance of consumption throughout the 2-h session. FIN also produced a dose-dependent decrease in brain ALLO levels. In conjunction with data in male mice, the present findings indicate that there are sex differences in the physiological regulation of ethanol intake patterns by GABAergic neurosteroids.
Figures
Figure 1. Effects of exogenous ALLO challenge on the temporal distribution of ethanol (10E) licks
The frequency of 10E licks recorded throughout the 2-hr drinking session is depicted in 20-min bins (panel A). Lick patterns during the initial 20-min of access were further examined as 10-min intervals (panel B) to investigate consumption onset. A collapsed mean of the baseline days that immediately proceeded each ALLO test session is shown as 0 mg/kg. Vertical bars represent the mean ± SEM of licks for 24 mice. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001 versus within-subject baseline (i.e., 0 mg/kg) for the respective session interval.
Figure 2. Effects of sub-chronic FIN administration and its subsequent withdrawal on daily ethanol dose (g/kg) consumed
Two doses of FIN were assessed: 50 mg/kg (panel A) and 100 mg/kg (panel B). Each data point represents the mean ± SEM ethanol intake for 13–14 FIN-treated or 10 VEH-treated mice. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 versus VEH-treated mice (i.e., 0 mg/kg) within a given drinking session.
Figure 3. Effects of FIN treatment (100 mg/kg) and withdrawal on the temporal distribution of ethanol (10E) licks
The frequency of 10E licks recorded throughout the 2-hr drinking session is depicted in 20-min bins (panel A). Lick patterns during the initial 20-min of access were further examined as 10-min intervals (panel B) to investigate consumption onset. Vertical bars represent the mean ± SEM of licks for 13 FIN-treated mice. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001 versus within-subject baseline for the respective session interval.
References
- Akk G, Li P, Manion BD, Evers AS, Steinbach JH. Ethanol modulates the interaction of the endogenous neurosteroid allopregnanolone with the α1β2γ2L GABAA receptor. Mol. Pharmacol. 2007;71:461–472. - PubMed
- Alele P, Devaud LL. Sex differences in steroid modulation of ethanol withdrawal in male and female rats. J. Pharmacol. Exp. Ther. 2007;320:427–436. - PubMed
- Barbaccia ML, Affricano D, Trabucchi M, Purdy RH, Colombo G, Agabio R, Gessa GL. Ethanol markedly increases "GABAergic" neurosteroids in alcohol-preferring rats. Eur. J. Pharmacol. 1999;384:R1–R2. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AA 10760/AA/NIAAA NIH HHS/United States
- R01 AA012439/AA/NIAAA NIH HHS/United States
- P60 AA010760/AA/NIAAA NIH HHS/United States
- K01 AA016849/AA/NIAAA NIH HHS/United States
- F31 MH 081560/MH/NIMH NIH HHS/United States
- AA 016849/AA/NIAAA NIH HHS/United States
- P50 AA010760/AA/NIAAA NIH HHS/United States
- AA 12439/AA/NIAAA NIH HHS/United States
- F31 MH081560/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical